A new platform for autoimmune diseases. Inducing tolerance with liposomes encapsulating autoantigens - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36481472/
Autoimmune diseases (AIDs) are caused by the loss of self-tolerance and destruction of tissues by the host's immune system. Several antigen-specific immunotherapies, focused on arresting the autoimmune attack, have been...
Conclusions: Specific PS-liposomes demonstrate great preventive and therapeutic efficacy in rheumatoid arthritis and myasthenia gravis. Thus, this work highlights the therapeutic potential of a platform for several autoimmunity settings, which is specific, safe, and with long-term effects.
Case report: Complex paraneoplastic syndromes in thymoma with nephrotic syndrome, cutaneous amyloidosis, myasthenia gravis, and Morvan's syndrome
Source : https://www.frontiersin.org/articles/10.3389/fonc.2022.1002808/full
BackgroundApart from myasthenia gravis (MG), thymoma is associated with a wide spectrum of autoimmune paraneoplastic syndromes (PNSs). Here, we report on a rare case presenting with four different PNSs, namely,...
Conclusions: This case serves to remind us that apart from MG, thymoma is also associated with other autoimmune PNSs such as membranous nephropathy, cutaneous amyloidosis, and Morvan’s syndrome. Autoimmune PNSs can present concurrently with or after surgical or medical therapy for thymoma. For Morvan’s syndrome post-thymectomy with LGI1...
Myasthenia gravis - a retrospective analysis of e-mail inquiries made to a patient organisation and specialized center to uncover unmet needs from patients and caregivers - BMC Neurology
Source : https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-022-02981-y
Background and aims Myasthenia Gravis requires expert treatment from specialized neurologists. In Germany, this treatment is mainly provided by 18 Integrated Myasthenia Centers (iMZ) accredited by the German Myasthenia Gravis...
Conclusions: MG sufferers have a high demand for timely advice. In the current setting, they address their requests to both iMZs and the DMG via e-mail. Our findings confirm that the DMG is highly trusted by patients and caregivers and is used to obtain second opinions. A relevant proportion of requests to the iMZ could be answered more...
Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature
Source : https://www.frontiersin.org/articles/10.3389/fmed.2022.950801/full
Immunotherapy with programmed death 1 (PD-1) inhibitor has shown activity as first- or second-line treatment for various metastatic human malignancies. Immune-related adverse events (irAEs) are now well-described, and most organ...
Conclusions: Here, we reported a case of concurrent myocarditis, myositis, diaphragmatic dysfunction, and esophageal hiatal hernia following treatment with PD-1 inhibitor sintilimab. Autoimmune myocarditis and neuromuscular side effects induced by ICI although rare can be severe and sometimes fatal. The severity for patients with myositis and...
Novel slow-binding reversible acetylcholinesterase inhibitors based on uracil moieties for possible treatment of myasthenia gravis and protection from organophosphate poisoning
Source : https://www.sciencedirect.com/science/article/abs/pii/S0223523422008510?via=ihub
Synthesis of bisuracils with pentylammonium group as the specific ligands for acetylcholinesterase vs. butyrylcholinesterase. * Lead compound 2h is a selective slow-binding inhibitor of acetylcholinesterase. * Administered to rat, compound...
/>
Conclusions: Moreover, compound 2h ameliorated muscle weakness in myasthenia gravis rat model with a lower effective dose and longer lasting effect than pyridostigmine bromide. Besides, it was shown that compound 2h has an effect of increasing efficiency of antidotal therapy as a pretreatment for poisoning by organophosphates.